Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus X TROZINE L A.
PHENERGAN VC vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine